Exercise and Dietary Lifestyle Intervention on Reducing Atrial Fibrillation Burden, Cardiac and Body Fat Mass.
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorUniversity of Eastern Finland
About this trial
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is strongly associated with obesity and excess body fat. Lifestyle interventions, including exercise and dietary modification, may reduce AF burden, but long-term randomized controlled trial evidence with objective AF burden assessment and advanced cardiac imaging is limited.
The MOVE-AF trial is a randomized controlled trial designed to evaluate whether a 12-month tailored exercise and dietary lifestyle intervention, compared with usual care, reduces atrial fibrillation burden and symptom severity and decreases cardiac and total body fat mass in overweight and obese adults with paroxysmal or persistent AF.
Eligibility criteria
Qualifiers
Age 18-75 years
Body mass index (BMI) ≥27 kg/m²
Documented atrial fibrillation (paroxysmal or persistent)
Ability to participate in exercise training and follow study procedures
Disqualifiers
Permanent atrial fibrillation
Unstable angina pectoris or acute coronary syndrome within the past 3 months
Participation in other lifestyle or drug weight reduction trials
Significant left ventricular dysfunction (ejection fraction <30%)
Trial design
Treatments tested in this trial
- Tailored Exercise and Dietary Lifestyle Program
- Usual Clinical Care
Treatment groups
158 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Eastern Finland
Lead sponsor
Kuopio University Hospital
Collaborator
Tampere University Hospital
Collaborator
UKK Institute
Collaborator
Hospital Nova, Central Finland
Collaborator
Source ClinicalTrials.gov